R A Hennigar

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Characterization of fatty acid synthase in cell lines derived from experimental mammary tumors
    R A Hennigar
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Biochim Biophys Acta 1392:85-100. 1998
  2. ncbi request reprint Clinicopathologic features of nephrogenic rests and nephroblastomatosis
    R A Hennigar
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Adv Anat Pathol 8:276-89. 2001
  3. ncbi request reprint Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy
    James A Tumlin
    Division Nephrology and the Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
    Semin Nephrol 24:256-68. 2004

Detail Information

Publications3

  1. ncbi request reprint Characterization of fatty acid synthase in cell lines derived from experimental mammary tumors
    R A Hennigar
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA
    Biochim Biophys Acta 1392:85-100. 1998
    ....
  2. ncbi request reprint Clinicopathologic features of nephrogenic rests and nephroblastomatosis
    R A Hennigar
    Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    Adv Anat Pathol 8:276-89. 2001
    ..Clinicians and surgeons are more aware of the impact that nephrogenic rests have upon patient management. Despite this progress, more data is needed to further define these lesions...
  3. ncbi request reprint Clinical presentation, natural history, and treatment of crescentic proliferative IgA nephropathy
    James A Tumlin
    Division Nephrology and the Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA
    Semin Nephrol 24:256-68. 2004
    ..Pulse solumedrol and intravenous cyclophosphamide effectively reduced peak serum creatinine, degree of proteinuria, the rate of decline in renal function, and the incidence of end-stage renal disease at 36 months...